HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$130.91
−0.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.4B | 1.0B | 829.3M | 660.1M |
| Cost of Revenue | 292.4M | 228.8M | 159.4M | 192.4M | 139.3M |
| Gross Profit | 1.4B | 1.2B | 855.9M | 636.9M | 520.8M |
| Operating Expenses | |||||
| R&D Expense | 102.4M | 81.5M | 79.0M | 76.4M | 66.6M |
| SG&A Expense | 238.0M | 207.1M | 154.3M | 149.2M | 143.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 100.2M | 76.7M | 71.0M | 73.8M | 43.1M |
| Total Operating Expenses | 440.5M | 365.2M | 304.4M | 299.3M | 253.3M |
| Cost and Expenses | 733.0M | 594.0M | 463.8M | 491.7M | 392.6M |
| Operating Income (EBIT) | 930.8M | 802.6M | 551.5M | 337.6M | 267.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 20.3M | 18.1M | 18.1M | 18.8M | 16.9M |
| Net Interest Income | (20.3M) | (18.1M) | (18.1M) | (18.8M) | (16.9M) |
| Other Non-Op Income/Expense | (347.4M) | (335.7M) | 5.7M | 10.8M | (18.6M) |
| Non-Operating Income (excl Interest) | 327.1M | 317.6M | (23.8M) | (29.5M) | 1.7M |
| EBT (Pre-Tax Income) | 583.3M | 466.9M | 557.1M | 348.3M | 248.9M |
| Income Tax Expense | 169.7M | 150.0M | 113.0M | 66.7M | 46.8M |
| Bottom Line | |||||
| Net Income | 413.6M | 316.9M | 444.1M | 281.6M | 202.1M |
| Earnings from Cont. Ops | 413.6M | 316.9M | 444.1M | 281.6M | 202.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 413.6M | 316.9M | 444.1M | 281.6M | 202.1M |
| Per Share | |||||
| Basic EPS | $3.52 | $2.64 | $3.50 | $2.13 | $1.48 |
| Diluted EPS | $3.35 | $2.56 | $3.43 | $2.10 | $1.44 |
| Revenue Per Share | $14.19 | $11.65 | $8.01 | $6.29 | $4.82 |
| Shares | |||||
| Basic Shares Outstanding | 117.3M | 119.8M | 126.8M | 131.9M | 136.8M |
| Diluted Shares Outstanding | 121.2M | 123.9M | 129.4M | 134.2M | 140.6M |
| Profitability Metrics | |||||
| EBITDA | 718.4M | 573.1M | 656.5M | 451.9M | 315.5M |
| D&A | 114.8M | 88.1M | 81.3M | 84.9M | 49.6M |
| EBIT | 603.6M | 485.0M | 575.2M | 367.1M | 265.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026